UHARA Hisashi

写真a

Affiliation

School of Medicine, Department of Dermatology

Job title

Professor

Homepage URL

http://www.shinshu-u.ac.jp/faculty/medicine/chair/i-hifu/index.html

Profile

 学歴、職歴（2018/10/1現在）

1979年 長野県立須坂高等学校卒
1986年 北海道大学医学部卒
信州大学医学部附属病院皮膚科 研修医
1987年 信州大学医学部附属病院皮膚科 助手
1988年 国立がんセンター研究所病理部及び附属病院皮膚科 任意研修医
1990年 諏訪赤十字病院皮膚科
1991年 信州大学医学部附属病院皮膚科 助手
1995年 信州大学医学部附属病院皮膚科 講師
2011年 信州大学医学部皮膚科 准教授
2017年 札幌医科大学医学部皮膚科学講座 教授

所属学会
日本皮膚科学会（代議員）
日本皮膚悪性腫瘍学会（評議員）
日本色素細胞学会（理事）
日本研究皮膚科学会（評議員）
日本臨床皮膚医会
日本皮膚病理組織学会
日本癌学会
日本癌治療学会
日本臨床腫瘍学会
The American Society of Clinical Oncology（ASCO）
The European Society for Medical Oncology（ESMO）
委員他
日本皮膚悪性腫瘍学会・悪性黒色腫薬物療法の手引作成委員
JCOG皮膚腫瘍グループ代表委員
日本臨床腫瘍学会 免疫チェックポイント阻害薬ガイドライン委員
WHO Classification of Skin Tumours, 4th edition 2018（協力著者）
著書
皮膚科診断をきわめる-目を閉じて診る、もうひとつの診断学（秀潤社、2016刊）
どう診る、どう治す、皮膚診療はじめの一歩（羊土社、2013刊）
皮膚科への一歩(電子書籍)
Web
うはら皮膚科（仮想クリニック）uhara.org

Hisashi Uhara, M.D., Ph.D.
CURRICULUM VITAE

PRESENT POSITION:
Professor & Chairman, Department of Dermatology
Sapporo Medical University School of Medicine, Sapporo, Japan
OFFICE ADDRESS: South 1, West 16, Chuo-ku, 060-8543, Japan
E-MAIL: uharah@sapmed.ac.jp
PHONE: +81-11-611-2111
FAX: +81-11-613-3739

EDUCATION AND TRAINING:
1986 MD: Hokkaido University School of Medicine, Sapporo, Japan
1986-1987 Resident in Dermatology, Shinshu University School of Medicine
1988-1990 Resident (Voluntary) in Pathology and Dermatology, National Cancer Center, Tokyo, Japan
1994 PhD: Shinshu University School of Medicine
2009 Visiting Scholar in Department of Pathology and Laboratory Medicine, UCLA (Prof. Cochran), CA, USA

APPOINTMENT:
1987 Assistant, Shinshu University School of Medicine
1990 Chief,Dermatology Clinic, Japanese Red Cross Society Suwa Hospital, Suwa, Japan
1991 Assistant, Shinshu University School of Medicine
1993-2003 Visiting instructor, Matsumoto Dental University, Shiojiri, Japan
1995 Senior Assistant Professor, Shinshu University School of Medicine
2011 Associate Professor, Shinshu University School of Medicine
2017 Professor & Chairman, Department of Dermatology, Sapporo Medical University School of Medicine

LICENSURE AND CERTIFICATE:
1986 National License of Physician
1995 Board Certificated Dermatologist
2008-2013 Specialist of Cutaneous Oncology

HONORS:
2007 Certificate of Recognition for Outstanding Posters in Diagnostic tools, The 21st World Congress of Dermatology (Buenos Aires）
2008 Best Clinical Award, the 72nd Annual Meeting of the Eastern Japan Division of Japanese Dermatological Association (Akita)
2010- The Best Doctors in Japan

EDITORIAL ACTIVITY:
2010- Editorial Board, International Journal of Clinical Oncology

MEMBERSHIP OF SCIENTIFIC SOCIETY:
Japanese Dermatological Association (representative)
The Japan Clinical Oncology Group (JCOG), Dermatologic Oncology Group (committee)
Japanese Skin Cancer Society (representative)
Japanese Society for Pigment Cell Research (representative)
Japan Society of Clinical Oncology
Japanese Cancer Association
ESMO
ASCO

MAJOR SCIENTIFIC INTERESTS:
Skin Cancers (management & oncogenesis), Liquid biopsy, Dermoscopy, Sonography, Lymphatic drainage pathway, Drug allergy, Sweating test
To the head of this page.▲

Education 【 display / non-display 】

  • 　
    -
    1986

    Hokkaido University   Faculty of Medicine  

To the head of this page.▲

Degree 【 display / non-display 】

  • Doctor of Medicine

To the head of this page.▲

Research Experience 【 display / non-display 】

  • 1990.02
    -
    2017.01

    Shinshu University School of Medicine  

  • 1990.02
    -
    1991.01

    諏訪赤十字病院皮膚科  

  • 1986.06
    -
    1988.08

    Resident in Dermatology, Shinshu University School of Medicine  

To the head of this page.▲

Professional Memberships 【 display / non-display 】

  • 　
    　
    　

    THE JAPANESE DERMATOLOGICAL ASSOCIATION

  • 　
    　
    　

    The Japanese Society for Plgment Cell Research

  • 　
    　
    　

    日本癌学会

  • 　
    　
    　

    ESMO

  • 　
    　
    　

    日本癌治療学会

display all >>

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life sciences   Dermatology  

To the head of this page.▲

Affiliation 【 display / non-display 】

  • Sapporo Medical University   University Hospital, Dermatology   Professor &Chairman  

To the head of this page.▲
 

Research Interests 【 display / non-display 】

  • cancer immunology

  • immune related adverse events

  • dermoscopy

  • genetics

  • Ultrasonography

display all >>

To the head of this page.▲

Papers 【 display / non-display 】

  • Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.

    Kenji Yokota, Tatsuya Takenouchi, Yasuhiro Fujisawa, Satoshi Fukushima, Hiroshi Uchi, Takashi Inozume, Yoshio Kiyohara, Hisashi Uhara, Kazuhiko Nakagawa, Hiroshi Furukawa, Shirong Han, Masaru Watanabe, Kazuo Noguchi, Naoya Yamazaki

    The Journal of dermatology    2024.03  [International journal]

    　View Summary

    Pembrolizumab demonstrated an acceptable safety profile and promising antitumor activity in Japanese patients with advanced melanoma in the phase 1b KEYNOTE-041 (Study of Pembrolizumab [MK-3475] in Participants With Advanced Melanoma) trial. To evaluate the long-term efficacy and safety of pembrolizumab in Japanese patients with advanced melanoma in KEYNOTE-041. The current analysis reports results of additional follow-up of approximately 12 months since the initial analysis. Eligible patients had locally advanced (unresectable stage III) or metastatic (stage IV) melanoma not amenable to local therapy and had received two or fewer prior systemic therapies. Pembrolizumab 2 mg/kg was given every 3 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Primary end points included safety, tolerability, and overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by independent central review. The data cutoff for this analysis was August 30, 2017. Forty-two patients were followed up for a median of 22.3 months (range, 2.63-30.82 months). The ORR was 24.3% (nine of 37 evaluable patients [95% confidence interval (CI), 11.8%-41.2%]). Two patients with partial response at the time of the initial analysis achieved complete response. The median overall survival (OS) was 25.1 months (95% CI, 13.1-not reached] and the 30-month OS rate was 46.3% (95% CI, 29.8%-61.3%). The median duration of response was not reached. Treatment-related adverse events (TRAEs) were reported in 78.6% of patients; the incidence of grade 3 to 5 TRAEs was 23.8%. No additional treatment-related deaths occurred since the initial analysis. Pembrolizumab provided durable antitumor activity and an acceptable safety profile in Japanese patients with advanced melanoma.

    DOI PubMed

  • Distinct induction pathways of heat shock protein 27 in human keratinocytes: Heat stimulation or capsaicin through phosphorylation of heat shock factor 1 at serine 326 and/or suppression of ΔNp63.

    Terufumi Kubo, Kenta Sasaki, Sayuri Sato, Tomoyuki Minowa, Tokimasa Hida, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Hisashi Uhara, Toshihiko Torigoe

    Biochemical and biophysical research communications   708   149817 - 149817  2024.03  [International journal]

    　View Summary

    Epidermal keratinocytes, forming the outermost layer of the human body, serve as a crucial barrier against diverse external stressors such as ultraviolet radiation. Proper keratinocyte differentiation and effective responses to external stimuli are pivotal for maintaining barrier integrity. Heat is one such stimulus that triggers the synthesis of heat shock proteins (HSPs) when cells are exposed to temperatures above 42 °C. Additionally, activation of the transient receptor potential cation channel subfamily V member 1 (TRPV1) occurs at 42 °C. Here, we explore the interplay between TRPV1 signaling and HSP induction in human keratinocytes. Both heat and capsaicin, a TRPV1 agonist, induce expression of HSP27, HSP70, and HSP90 in keratinocytes. Interestingly, pharmacological inhibition of TRPV1 attenuates heat-induced HSP27 expression, but not that of HSP70 or HSP90. Furthermore, both heat and capsaicin stimulation result in distinct phosphorylation patterns of heat shock factor 1 (HSF1), with phosphorylation at serine 326 being a common feature. Notably, genetic manipulation to mimic dephosphorylation of HSF1 at serine 326 reduces HSP27 levels. Additionally, ΔNp63, a key regulator of epidermal differentiation, negatively modulates HSP27 expression independently of HSF1 phosphorylation status. While heat stimulation has no effect on ΔNp63 expression, capsaicin reduces its levels. The precise role of TRPV1 signaling in keratinocytes warrants further investigation for a comprehensive understanding of its impact on barrier function.

    DOI PubMed

  • Melanoma incidence on the non-weight-bearing areas of the sole.

    Kazuki Furudate, Junji Kato, Kohei Horimoto, Sayuri Sato, Tokimasa Hida, Masahide Sawada, Tomoyuki Minowa, Hisashi Uhara

    The Journal of dermatology    2024.02  [International journal]

    DOI PubMed

  • Characterization of CD4 T-cell phenotype in human leukocyte antigen class II-positive acral melanoma.

    Nayuha Shogase, Tomoyuki Minowa, Junji Kato, Kohei Horimoto, Sayuri Sato, Tokimasa Hida, Yoshihiko Hirohashi, Toshihiko Torigoe, Hisashi Uhara

    The Journal of dermatology    2023.12  [International journal]

    DOI PubMed

  • Four cases of gnathostomiasis due to the ingestion of raw <i>Salangichthys microdon</i>

    Takahiko Abe, Tokimasa Hida, Takafumi Kamiya, Kanako Ebata, Shintaro Sugita, Rie Kaneko, Mio Tanaka, Haruhiko Maruyama, Akira Suzuki, Hisashi Uhara

    The Journal of Dermatology ( Wiley )   2023.10

    DOI

display all >>

To the head of this page.▲

Books and Other Publications 【 display / non-display 】

  • WHO Classification of Skin Tumours, 4th edition 2018

    UHARA Hisashi( Part： Joint author, melanoma, melanocytic nevus, mongolian spot)

    World Health Organization  2018.09

To the head of this page.▲

Misc 【 display / non-display 】

  • Comprehensive single-cell immune profiling of tumor-infiltrating lymphocytes in acral melanoma

    箕輪智幸, 箕輪智幸, 村田憲治, 廣橋良彦, 宇原久, 鳥越俊彦

    日本病理学会会誌   112 ( 1 )  2023

    J-GLOBAL

  • MYO5A-NTRK3融合遺伝子を検出したatypical Spitz tumor

    佐藤 さゆり, 肥田 時征, 井戸川 雅史, 黄倉 真恵, 宇原 久

    日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  132 ( 5 ) 1363 - 1363  2022.05

  • 病理組織学的に顕著なロゼット様構造を呈したALK陽性atypical Spitz tumor

    箕輪 智幸, 肥田 時征, 堀本 浩平, 加藤 潤史, 神谷 崇文, 杉田 真太朗, 井戸川 雅史, 宇原 久

    日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  131 ( 5 ) 1417 - 1417  2021.05

  • カスタムパネルシーケンスを用いた日本人メラノーマのドライバー遺伝子の検出

    肥田 時征, 井戸川 雅史, 堀本 浩平, 加藤 潤史, 佐藤 さゆり, 藤岡 茉生, 丹下 正一朗, 時野 隆至, 宇原 久

    日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  131 ( 5 ) 1363 - 1363  2021.05

  • Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).

    Yasuhiro Nakamura, Kenjiro Namikawa, Koji Yoshino, Shusuke Yoshikawa, Hiroshi Uchi, Katsunobu Goto, Yoshiyuki Nakamura, Satoshi Fukushima, Yukiko Kiniwa, Tatsuya Takenouchi, Hisashi Uhara, Toru Kawai, Naohito Hatta, Takeru Funakoshi, Yukiko Teramoto, Atsushi Otsuka, Haruki Doi, Dai Ogata, Shigeto Matsushita, Naoya Yamazaki

    JOURNAL OF CLINICAL ONCOLOGY ( AMER SOC CLINICAL ONCOLOGY )  37 ( 15 )  2019.05

    Research paper, summary (international conference)  

    DOI

display all >>

To the head of this page.▲

Awards 【 display / non-display 】

  • Best Doctors in Japan (2010-)

    2010  

  • 第72回日本皮膚科学会東部支部学術大会学会賞（Best Clinical Award）

    2008  

  • Certificate of Recognition for Outstanding Posters in the Category Invasive&non invasive techniques - Diagnostic tools

    2007  

To the head of this page.▲

Research Projects 【 display / non-display 】

  • メラノーマにおける複数の変異遺伝子を候補とした個別化リキッドバイオプシー法の確立

    基盤研究(C)

    Project Year :

    2022.04
    -
    2025.03
     

    宇原 久

  • Characterization of the intratumoral ecosystem in melanoma by single-cell RNA-seq analysis

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2019.04
    -
    2022.03
     

    UHARA HISASHI

    　View Summary

    The aim of the study is to establish of the method to obtain the single-cell gene expression of RNA in melanoma cells from the resected tumor samples. The method is planned according to the following steps (Hashimoto S, Scientic Reports 7;14225, 2017). In the first case, over expression of MAPK pathway-related molecules and HLA class 1 and lower expression of HLA class 2 and PD-L1 were observed in melanoma cells in 2 of 5 clusters. However, in next 5 examined cases, synthesis of cDNA of a single cell was not stable. We thought that melanin blocked the enzyme activity. We have tried several methods to remove melanin from tissue samples, however it has not been sufficient yet. Now, we test other methods including filters.

  • 美白化合物のメラノーマ細胞障害作用を利用した新規メラノーマ治療薬の開発

    奨励研究

    Project Year :

    2019
    　
    　
     

    黄倉 真恵, 宇原 久, 肥田 時征

    　View Summary

    BRAF遺伝子変異を有するメラノーマには分子標的薬が奏効するものの、のちに薬剤耐性が生じる場合が多い。本研究は、分子標的薬の耐性をアスコルビン酸、ロドデノールの併用で克服できるかどうかを検討した。結果、アスコルビン酸はBRAF/MEK阻害剤耐性メラノーマ細胞株SK-me1-23DT, ロドデノールはBRAF/MEK阻害剤耐性メラノーマ細胞株A375DTに強い細胞障害を誘発した。以上の結果から、アスコルビン酸とロドデノールは、分子標的薬(BRAF/MEK阻害薬)による耐性を克服しうる治療薬の候補となり得ることがわかった。

  • メラノーマ患者の血液循環腫瘍由来RNAを用いた病勢モニタリング法の確立

    Project Year :

    2016
    -
    2018
     

    宇原久

    Authorship： Principal investigator

  • 血液循環腫瘍DNAを用いたメラノーマ患者の遺伝子解析

    Project Year :

    2014
    -
    2016
     

    芦田敦子

display all >>

To the head of this page.▲
 

Committee Memberships 【 display / non-display 】

  • 　
    　
    　

      評議員、予後統計調査委員会委員

  • 　
    　
    　

      代議員、ガイドライン作成委員会委員

To the head of this page.▲